Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 10/20 | 0.57 |
| ▸ | ITK | Q08881 | 1/20 | 0.54 |
| ▸ | PGR | P06401 | 3/20 | 0.50 |
| ▸ | AURKA | O14965 | 2/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.49 |
| ▸ | MAP2K7 | O14733 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3971858 | 0.90 | MAP2K4 (0.56) | MAP2K4ITKPGRAURKAAURKB | |
| SCHEMBL3966505 | 0.87 | MAP2K4 (0.56) | MAP2K4AURKAMAP2K7 | |
| SCHEMBL3967750 | 0.87 | MAP2K4 (0.56) | MAP2K4ITKAURKAMAP2K7 | |
| SCHEMBL3968853 | 0.87 | MAP2K4 (0.57) | MAP2K4PGRAURKAKDRAURKB | |
| SCHEMBL3966208 | 0.87 | MAP2K4 (0.56) | MAP2K4ITKAURKAKDRMAP2K7 | |
| SCHEMBL3972513 | 0.86 | LMNA (0.53) | MAP2K4KEAP1NFE2L2GAA | |
| SCHEMBL3971863 | 0.85 | MAP2K4 (0.66) | MAP2K4MAP2K7 | |
| SCHEMBL3971253 | 0.85 | TP53 (0.56) | MAP2K4GAA | |
| SCHEMBL3973325 | 0.83 | MAP2K4 (0.51) | MAP2K4AURKAMAP2K7 | |
| SCHEMBL3969942 | 0.83 | MAP2K4 (0.54) | MAP2K4ITKAURKAAURKBMAP2K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517901-B2 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517901-B2 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517901-B2 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC (US) | 2009-04-14 | — | — | US | disclosed |
| US-20070049633-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
| US-20070049633-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
| US-20070049633-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049633-A1 | p38 MAP kinase inhibitors and methods for using the same | MAPK1, MAP3K1, MAP3K20 | MAP2K4 101/4885ITK 2336/4885PGR 998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.